Healthcare Meets Electronics: Event Assesses the Opportunities

Registrations for the inaugural Healthcare Sensors Innovation event in Cambridge on 25-26 September is exceeding all expectations and nears venue capacity. The event is successfully bringing together the linchpins of the healthcare industry with the electronics industry to explore the opportunity in two specific areas: point of care diagnostics and continuous monitoring.

The event addresses the needs and opportunities for faster diagnosis, remote monitoring and treatment and the opportunity for new revenue streams, alongside the progress of the enabling technologies including biosensors, flexible electronics, low power electronics and connectivity.

Attendees include pillars of the healthcare industry such as AstraZeneca, GSK, Baxter Healthcare, Boston Scientific, Smith & Nephew, W.L. Gore and LifeScan.

Uniquely these organizations are brought together with those in electronics and electronics materials, including Analog Devices, Philips, STMicroelectronics, Samsung, Sun Chemical, Maxim Integrated, Molex, Nissha, Henkel, and many others.

Nadia Tsao, Senior Technology Analyst who runs the Life Sciences research practice at IDTechEx, reports, “The success of this event is down to its focus on two core growth areas: continuous monitoring and point-of-care diagnostics. With aging populations, shortage of medical staff, and the need to rapidly diagnose and treat based on accurate measurement data, this event focuses on pragmatic applications of technology innovations that are occurring now, such as the $7.5 billion electronic skin patches market.”

The event will be held at Clare College, part of the University of Cambridge. Cambridge was selected for the event location due to the large number of healthcare and pharmaceutical companies in the area and many world leaders in electronics have significant development bases there.

Healthcare Sensor Innovations is market led and analyst driven, meaning that industry analysts IDTechEx have devised the event based on showcasing market challenges and needs and how they are being addressed. Learn more and register now at www.HealthcareSensorInnovations.com

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy contact info@IDTechEx.com or visit www.IDTechEx.com.

Wearables Accelerate Healing of Chronic Wounds

Though the human body has a tremendous capability to heal itself, wound healing can stall and create chronic non-healing wounds due to a variety of reasons such as ischemia, bacterial contamination, and chronic inflammation. IDTechEx Research have published a comprehensive report, “Advanced Wound Care Technologies 2020-2030”, explaining why the incidence of chronic wounds is set to rise drastically in the next 10 years, and how electronic devices and other emerging technologies can address this upcoming challenge.

Previously, IDTechEx Research have reported on several different roles that electronics can play in the wound care process, including even preventing wounds from forming in the first place. IDTechEx has also written about smart bandages as the future of wound care. These smart bandages will monitor wounds and deliver directed therapy. While these smart bandages are still in development and thus a few years away from commercialization (and several more years away from mass adoption), there are already electronic bandages that are in use today in the care of chronic wounds.

Pulsed Electromagnetic Field Therapy

One such example of an electronic bandage is the RecoveryRx from BioElectronics. The RecoveryRX is a small device with a loop within which pulsed electromagnetic field (PEMF) therapy is delivered. Though PEMF therapy is primarily used in pain relief, the device has been shown to promote wound healing and reduce wound pain. It can easily be incorporated into wound dressings. One of the proposed mechanisms of action for PEMF is the reduction of inflammation and swelling at the wound. This device received FDA market clearance in July 2019.

Oxygen Therapy

Oxygen is critical to the wound healing process, and many patients undergo hyperbaric oxygen therapy (HBOT) to treat their chronic wounds. High concentrations of oxygen can trigger the growth of new blood vessels and production of collagen, both key to the wound healing process. However, HBOT is costly and inconvenient to patients. Inotec AMD have developed the Natrox, a portable device that supplies a high concentration of oxygen directly to the wound bed via a patch. The device, about the size of a mobile phone, generates oxygen via electrolysis.

Negative Pressure Wound Therapy

Finally, and by far the most common form of electronic bandage that is in use today, is the ultraportable negative pressure wound therapy (NPWT) device. NPWT refers to the application of negative pressure on the wound, which may be supplied by wall suction in the hospital, reusable, portable units, or increasingly, disposable ultraportable devices that fit within the patient’s pocket. These devices typically consist of a pump that provides the negative pressure, and a small canister to collect the exudate from the wound. With these ultraportable devices, patients now have the freedom to walk around and perform their daily activities while receiving NPWT. By increasing focus on patient mobility, and speeding up discharge from care facilities, ultraportable NPWT devices deliver significant benefit to both the patient and the healthcare system. Major companies with ultraportable NPWT devices include Smith & Nephew, ConvaTec, and Acelity.

To learn more about other uses of electronic skin patches, please refer to the IDTechEx Research report: “Electronic Skin Patches 2019-2029”. To find out more about Life Sciences research available from IDTechEx visit www.IDTechEx.com/LifeSci or to connect with others on this topic, IDTechEx Events is hosting: Healthcare Sensor Innovations 2019 Conference on 25 – 26 September 2019 in Cambridge, UK. Please visit www.IDTechEx.com/Cambridge.

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy contact research@IDTechEx.com or visit www.IDTechEx.com.

First medically approved back pain app in EU and UK aims to end the nationwide epidemic of back pain in UK offices

London, UK – Bad posture among UK office employees is a nationwide epidemic. Sitting at desks all day, slouching over computers and a general sedentary lifestyle has led one in five Brits to give up their job or reduce hours because of their condition1. Experts behind Kaia, the first and only medically approved back pain app in the EU and UK, want to end the nationwide epidemic of back pain in UK offices, and claim that a few simple changes in the workplace can help to reduce the risk.

‘Epidemic levels‘

According to WHO, back pain is the leading global cause of disability worldwide.2 Meanwhile, in the UK, an estimated one-third of the adult population are affected by back issues each year.3 And according to the Office for National Statistics, back pain accounts for almost 31 million days of work lost annually costing the UK economy £14 billion a year.4 In another study, 63% in higher managerial jobs attributed their back pain to bad posture, and took more days off sick for back pain than any other type of employee.

The Kaia back pain app was developed by digital therapy company Kaia Health in conjunction with physiotherapists, orthopaedic surgeons and clinical psychologists. The app offers video exercises with education, physiotherapy and psychological strategies. Users can chat online with a physiotherapist or sports scientist for motivation and exercise-related questions.

Video: Kaia back pain app unveils 10 exercises to relieve back pain at work:

http://ow.ly/SWcq30pomaN

Sedentary office occupations can cause back pain as a result of inactivity between back muscles and the spine – but this is not the only factor. A combination of high workload, posture, job dissatisfaction or fear over termination can increase the occurrence of back pain at work.

In an independent clinical study published recently in NPJ Digital Medicine, patients using Kaia reported significantly lower pain levels compared to the control group treated with physiotherapy and online education.

A few simple changes can help to reduce the risk of back pain in the workplace. These include:

●        Walk and talk during phone calls

●        Take a break from the screen every 30 minutes for at least two minutes

●        Exercise regularly at your desk including arm stretches and neck rolls

●        Walk over to and talk with a colleague rather than emailing them

●        Arrange a workplace assessment to optimise the seating position and workstation

●        Meditate for 10 minutes. Be mindful of the influence workplace stress and strain has

●        Sit correctly with your thighs at right angles to your body or sloping slightly down

Stephan Huber, Chief Medical Officer at Kaia Health, says: at Kaia says: “The core problem is our modern, sedentary working life. We’re hunched at desks all day and this puts a strain on our back. We’re encouraging UK employers to adopt a holistic approach to tackling back pain in and out of the workplace – this could include increased access to exercise and relaxation like the Kaia app offers. Implementing these measures systematically for workers could lead to a more active way of dealing with the condition – and this will help to alleviate back pain and reduce the strain on the NHS.”

Kaia can be downloaded via the App Store and Google Play with a 7-day free-trial.

Strengthening Allied Health Professionals’ contribution to health and wellbeing

An Allied Health Professions Director from NHS Grampian has accepted the position of Visiting Professor at Robert Gordon University (RGU) to collaboratively support changes in healthcare delivery to meet the challenges of an ageing population.

Delivering the integrated healthcare models of tomorrow will mean that training for Allied Health Professionals (AHPs), such as Physiotherapists, Dietitians and Occupational Therapists, will have an increased focus on prevention, early intervention and becoming first point of contact practitioners.

The appointment of Susan Carr, NHS Grampian’s Director of Allied Health Professions and Public Protection, as Visiting Professor deepens the collaborative development of RGU’s demand-led teaching and research in line with the workforce needs of the sector.

Susan said: “The very nature of an ageing population means that there is an increasing demand for Allied Health Professionals who have a very important role in keeping people active, independent, living at home and enjoying life. We also have to be aware that as people get older they can become frail and vulnerable, and this is where a good understanding of the public protection aspect comes in.

“RGU has always been proactive in this area. There’s a high level of expertise at the university, and it’s about finding ways we can work together to continuously improve that. The better we support students coming out of university, the better equipped they are to do their job and support that wider public protection role.”

The Full Review of the Shortage Occupation List in May, by the Migration Advisory Committee, highlights the healthcare challenges the UK faces, including an ageing population and an increase in young adults living with disabilities. The Scottish Government’s Active and Independent Living Programme outlines how AHPs have a key role in supporting Scotland through these challenges by transforming the way AHPs work with the public to co-create health and wellbeing.

RGU will work with Susan and NHS Grampian to provide quality placement opportunities alongside NHS staff and a curriculum collaboratively designed to meet the challenges of the industry. The collaboration will also support students’ contribution to the multi-agency public protection agenda to keep children, young people and adults safe from harm and give them the confidence to help those in vulnerable situations.

Head of The School of Health Sciences at RGU, Dawn Mitchell, said: “We’ve worked closely with Susan and her team over a number of years, and this partnership and collaboration has helped to shape the development of our Allied Health Professions’ educational portfolio.

“Offering the position of Visiting Professor recognises Susan’s extensive experience and influence, and her commitment to RGU’s School of Health Sciences.”

Susan takes a lead role in working with the Scottish Government, NHS Education for Scotland and practice colleagues through key membership in the national Allied Health Professions Directors’ group. Through close collaboration with RGU, Susan uses this influence to help policy makers and service providers gain awareness and increase support for the educational developments being created in response to rising demand for AHPs.

93-year-old surgeon shares ‘Tales of the Operating Theatre’

A 93-year-old surgeon who joined the NHS in its first month has launched a new book bringing to life significant medical moments from throughout history and his 71 years in practice.

Professor Harold Ellis CBE launched the book entitled Tales of the Operating Theatre and other essays’, as part of the AfPP annual Residential Conference held in York on 10 August 2019.  

Based on a collection of Ellis’ previously written journal papers, including the popular Surgical Firsts, The Name Behind the Instrument and Notable Women, the book comprises first-hand accounts of some of the most remarkable moments in medical history.

From Horatio Nelson’s famous amputation through to the introduction of anaesthesia and Marie Curie’s discovery of radium, the easy-to-read book will appeal to everyone, regardless of their association with the perioperative environment.

Gina Graydon, editorial assistant at AfPP who has been helping Harold with the publishing of his book said: “Professor Ellis has been writing for the AfPP Journal of Perioperative Practice for over 20 years and never fails to deliver a well written and interesting paper.

“We decided to provide him with the practical support required to release a book so that those outside of the operating theatre professions could enjoy his stories.”

“He really is a remarkable character, and this really comes to light throughout the entirety of his book.”

Professor Ellis, who was awarded a CBE for his services to surgery in 1987, first qualified in medicine at the University of Oxford in 1948, the very year and month that the National Health Service came into existence.

After spending two years training as a house surgeon in Oxford, he went on to practice as a graded surgical specialist in the Royal Army Medical Corps until 1952.

Immersing himself in a surgical career on his return, he spent the next eight years working as a senior registrar before founding the academic surgical unit at Westminster Medical school in 1960, where he practiced as a professor of surgery until his retirement in 1989.

Refusing to let go of his dedication to the healthcare system, he took on the position of clinical anatomist at Kings College London in 1993 and still remains in the position today.

In the final chapter of his book, Professor Ellis talks of his impressive career and how his views of the NHS have changed over the last seven decades.

“I have to confess that at the start of NHS, I barely even noticed it, but I later realised it’s importance and the benefits it brought.

“I became very proud that the United Kingdom pioneered this universal health scheme, free at the point of entry and not dependent on the patient’s bank balance, but this soon became an issue.

“But there was no way that anyone in those exciting early days of the NHS could have possibly foreseen that over the years, there would be spiralling costs as medical and surgical care became more sophisticated and expensive.

“As far as I’m concerned, the National Health Service holds a special place in the hearts of the British Public as well as in the hearts of all its employees.”

Professor Ellis’ book is already proving to be popular with over 100 copies sold at the launch event.

To purchase a copy, please email orders@afpp.org.uk or call 01423 881300.

Stellar line-up of speakers confirmed for AfPP Residential Conference

The Association for Perioperative Practice (AfPP) has revealed a stellar line-up of speakers and exhibitors for its new-look Residential Conference, due to be held between 8 and 11 August at York University.

The once-a-year conference aims to bring together all members of the perioperative team, students and medical practitioners from across the globe for a three-day fun-packed and educational event.

AfPP have evolved the conference dramatically since its first appearance in the 60’s, attracting over 40 medical technology exhibitors to this year’s event, as well as some of the most inspiring speakers in the industry.

Speaking for the first time, Chris Pointon, co-founder of the #hellomynameis campaign, will deliver a must-hear speech about the importance of introductions in healthcare, covering the inspirational story of his late wife Dr Kate Granger MBE.

Kate fought a rare type of cancer and established the campaign as a result of her own experiences during post-operative sepsis, after making the stark observation that many care staff didn’t introduce themselves before delivering her care. Since her passing in 2016, Chris has continued the campaign in her memory.

Other inspiring individuals to headline the event include:

·         Jules Wyman- Coach and Professional Speaker – In her talk ‘how infectious are you?’ Jules shares her personal journey through the health care system in the UK and the impact that two particular consultants had on her.  She discusses how others can learn from them to make a difference to themselves, their work and their home.  

 

·         Adam Alderson of The Yorkshire Yak– As one of only four people in the world to have survived eight organ transplants and radical tumour de-bulking surgery, Adam demonstrates the difference that organ donations can make to those dealing with terminal diagnosis. Adam will speak of his recovery and why he decided he wanted to take on one of the world’s biggest motoring challenges – The Mongol Rally.

·         Rob Tomlinson, Junior Charge Nurse and creator of the 10,000 Feet Initiative- As creator of the 10,000 Feet Initiative- an airline safety initiative adopted in East Lancashire to reduce the risk of hospital theatre errors caused by noise, distraction and poor communication, Rob will discuss ways to stop all unnecessary noise in a theatre and allow practitioners at all levels to concentrate completely on their work.

 

·         Dr Harriet Palfreyman, Historian of Medicine at the Centre for the History of Science, Technology and Medicine at the University of Manchester- Harriet will deliver her winning presentation, The Time Travelling Operating Theatre: How the past can inform the future. The public engagement project stages recreations of surgeries from three time periods and has been delivered in museums across the world.

In addition, Allan Marriott, Maxine Page, Dr Steve Ray, Stryker Surgical, Linda Hindle, Oliver Tierney, Scarlett McNally, Adrian Jones, Helen Bevan, Mona Gukian Fisher, Joy Ongcachuy and Gail Lowdon will deliver a variety of speeches, educational workshops and silent lectures between them, some of which account for up to 12.5 CPD accredited hours.

Delegates will also be given the opportunity to meet with, and hear from, 93-year-old author and former vice president of the Royal College of Surgeons, Professor Harold Ellis CBE, who will be on hand to sign copies of his latest book, Stories from the Operating Theatre and Other Essays.

Professor Ellis’ speech, ‘The early days of the NHS, an old surgeon looks back’, also forms this year’s Siobhan Ranking lecture, which is delivered in honour of a past AfPP president who died in Service.

CEO of the association, Dawn Stott said: “We’re extremely excited about our line-up of speakers this year and can’t wait to welcome them to York University.

“Some of our speakers will be speaking for the first time and some have shared their stories with us before, but each will inspire and educate all those who attend.

“This year’s agenda ensures there’s something for everyone, in fact, I think many delegates will struggle to choose who to listen to.”

The 2019 Residential Conference is this year sponsored by Uniserge, Stryker Surgical, Aspen, 3M, Spire Healthcare, Farla Medical, Royal Cornwall NHS Trust, BD Medical Technology and ConMed, and has already seen 370 people book to attend.

For more information on the agenda or to grab a last-minute day ticket, please visit https://www.afpp.org.uk/events/residential-2019 or call 01423 882 969.

Diabetes Digital Media’s Chief Operating Officer, Charlotte Summers, Wins Prestigious Future Stars Award for ‘Digital Leader’

The awards ceremony took place on Thursday 27th June at The Brewery, Chiswell Street, London. Guests were treated to a star-studded ceremony which included a banquet dinner, networking drinks and awards ceremony. The evening was sponsored and supported by leading global brands, including: London Stock Exchange Group, Sky Betting and Gambling, Rolls Royce, J.P Morgan, Just Eat and Frank Recruitment. The judging panel was comprised of five industry-leading businessmen and women, including Marianne Calder, Global Head of Insite Sales at BT and David Ivell, Chief Technical Officer at Semta.

Speaking of her recent award, Charlotte, says “[Insert Quote].” Charlotte was up against seven other high-flying, entrepreneurial young women, including Verena Paprik, Chief Marketing Officer at UK-headquartered MusicGIF network TuneMoj who is listed on Forbes 30 Under 30.

Charlotte is a published clinical author and expert in digital health interventions and behavioural change/psychology. She is also Chief Operating Officer and the driving force behind DDM, based in the heart of England at the University of Warwick Science Park.

Starting out in 2003 as Diabetes.co.uk, the world’s first peer-to-peer online support community for people with diabetes, DDM has evolved to become Europe’s largest and most engaged diabetes community, providing peer-to-peer support, information, and education to over 40 million users annually. Charlotte’s focus lies in creating and delivering digital education programs with proven health outcomes and cost savings. Her passion lies in creating offline accountability and behavioural change in a digital age.

In 2015, she was responsible for the launch of the award-winning Low Carb Program. So far over 416,000 people have downloaded the program which shows people how to lose weight, reduce their HbA1c, become active and in some cases put type 2 diabetes in remission. Charlotte continuously drives this project forward, and in 2018, the Low Carb Program secured QISMET and CE accreditation, meeting all the requirements for delivery within the NHS. A three-year study following the one-year outcomes of 1000 patients for type 2 diabetes, prediabetes and general wellbeing is published in the Journal of Medical Internet Research Diabetes, an industry leading diabetes journal.

At just 29 years old, she has been accredited with a number of accolades and this Future Stars award adds to a growing list. A disruptor in the Sunday Times Maserati 100 List 2017, Finalist for the First Women of Healthcare from First Women Awards, Management Today as one of their “35 Women Under 35” and Finalist in the 2018 NatWest Great British Entrepreneurs Awards.

She holds a BSc Hons degree in Psychology and has been part of the DDM team since 2012. Charlotte manages operations as well as implementing persuasive methods to improve optimisation. She directs, co-ordinates and oversees marketing, editorial and web development teams, manages public relations, community development projects and human resources. Charlotte assisted in growing the market-leading community to over 103m page views by 24.7m users in 2017, and over 29.8m page views by 6.9m users from January to March 2018 alone.

Last year (2018), Charlotte co-authored a paper, Outcomes of a Digitally Delivered Low-Carbohydrate Type 2 Diabetes Self-Management Program: 1-Year Results of a Single-Arm Longitudinal Study, alongside Dr Laura Saslow (Assistant Professor University of Michigan School of Nursing) and Dr David Unwin (NHS Innovator of the Year 2016). This paper has been published in the Journal of Medical Internet Research and has proven that a low carb diet is effective in improving the health of people with type 2 diabetes and in many cases putting it into remission.

Charlotte is a regular speaker at industry seminars and conferences, specifically about the future of diabetes and wider healthcare education. She has previously spoken at Low Carb Breckenridge in Colorado on “180,000 anecdotes: The Low Carb Program” and at the Diabetes Professional Care Conference on “Play Your Carbs Right”. More recently, she was a guest speaker at the 39th Annual Meeting & Scientific Sessions hosted by the Society of Behavioural Medicine in New Orleans, PHC structures for Optoelectronics in London and Web Summit in Lisbon Portugal.

Medication-free treatment for depression launches in the UK

Flow, a medical device company, launches a medication-free treatment for depression comprising a brain stimulation headset and therapy app. In Europe, Flow is classified as a Class IIa medical deviceintended for use as a treatment for depression and was certified by BSI’s Netherlands notified body. It is the first approved treatment of its kind in Europe available to buy and use at home. Randomised controlled trials published in theNew England Journal of Medicine and the British Journal of Psychiatry showed that brain stimulation, of the type used in the Flow headset, had a similar impact to antidepressants but with fewer and less-severe side effects.1,2,3

Flow is starting talks with the NHS to have its brain stimulation headset available on prescription. In 2019, Flow will also be working with the U.S. Food and Drug Administration (FDA) to seek regulatory clearance in the U.S.

People diagnosed with depression often have a lower neural activity in their left frontal lobe, the part of the brain controlling important cognitive skills, including emotional expression. The Flow headset uses transcranial direct current stimulation (tDCS), a form of neurostimulation that delivers constant, low direct current via electrodes on the head to stimulate neurons in this area and help rebalance activity.  The brain stimulation delivered in the Flow headset is technically and clinically equivalent to devices used in these randomised controlled trials.

“By combining tDCS with behavioural therapy, the Flow team has created a powerful medical device treatment. I have seen first-hand the possibilities this technique has in providing a treatment for unipolar depression without the several adverse effects associated with pharmacological therapies,” said Andre Russowsky Brunoni, Psychiatrist, Associate Professor at the University of São Paulo Medical School and co-author of the New England Journal of Medicine andBritish Journal of Psychiatry study.

Treatment typically lasts for 30 minutes per session, with 18 sessions over 6 weeks. Continued treatment is then possible for 1-2 sessions per week.

During brain stimulation, users engage with a virtual therapist, via an app. This features videos and advice about depression, and how to reduce symptoms, using recent expert knowledge from the fields of sleep, nutrition, fitness and meditation.

“We want to support the improvement of the current standard of care for people living with depression by increasing treatment choice and empowering patients to self-manage their symptoms at home with effective, non-pharmacological, alternatives,” said Daniel Mansson, Co-Founder and CEO of Flow.

Depression statistics

Over 300 million people of all ages and genders suffer from depression, and it is the leading cause of disability worldwideaffecting more women than men.5 Nearly one in four adults in the UK are affected by a mental illness.6 Suicide is the most common cause of death for men aged 20-49 years in England and Wales.7 The economic costs of mental illness in England is estimated at £105.2 billion annually.8 And one in three work sickness notes handed out by GPs are for mental health reasons, including depression.9

About the clinical evidence1,2,3,4

In one randomised controlled trial (RCT), 245 patients diagnosed with unipolar depression were randomly assigned to three groups. The first group were assigned to the antidepressant escitalopram (n=91), the second to tDCS (n=94) and the third to a placebo (n=60). The primary outcome measure was the change in the 17-item Hamilton Depression Rating Scale (HDRS-17) score (range, 0 to 52, with higher scores indicating more depression). Within the study, 24% of patients using tDCS completely overcame their depression. 41% found that at least half of their symptoms disappeared after 6 weeks, whilst 47% of patients taking antidepressants found that at least half of their symptoms disappeared in the same period.1 And in the largest review of its kind, with over 33,000 stimulation sessions, it was concluded that tDCS did not produce any serious adverse effects or irreversible injuries.3

In a meta analysis from 2016 comprising 6 RCT studies (n=289) it was shown that 23% of patients using tDCS completely overcame their depression whilst 34% found that at least half of their symptoms disappeared.2

And a recently published systematic review and network meta-analysis examining brain stimulation for the acute treatment of major depressive episodes in adults concluded that “we found tDCS to be efficacious across outcomes in both pairwise and network meta-analyses. Given that tDCS tends to be a less expensive treatment than transcranial magnetic stimulation, ECT, or psychotherapy, this finding is particularly relevant for policy makers who might consider tDCS as a clinical therapy outside the research setting.”4

Those considering using Flow should have a diagnosis of depression and consult with their GP or healthcare professional beforehand. Individuals should not stop their current treatment for depression but seek advice from their GP or healthcare professional before making any changes to their current treatment protocol. Flow is not recommended for certain groups, including pregnant women and people under 18 years of age. For more information, click here.

Based in Sweden, Flow was developed by clinical psychologist Daniel Mansson and neuroscientist Erik Rehn, together with a team of prominent researchers in the field of psychiatry and brain stimulation.

The Flow headset retails at £399 and can be purchased here. The Flow virtual therapy app, available on iOS, is free and can be downloaded here.

Biotechnology Disruptors Report – 2019

Chicago, IL: PreScouter, a Chicago-based research intelligence company, has released a detailed report on the recent advances in biotechnology and how these advances are helping promote better treatments of disease and slow down the aging process. With the biotechnology sector expected to reach nearly 727 billion USD by 2025 and with the enormous number of advances in the field every month, PreScouter identifies in this report which innovations are particularly likely to have an impact in the next 5 to 10 years and what groups are powering these discoveries.

Dr. Vidhya Sivakumaran, the author of the report, notes that while advances in biotechnology open up the treatment and even the cure of chronic disease, “one of the current barriers facing biotechnology moving forward is purely logistical; a number of steps in the research process face logistical hurdles which have yet to be overcome by the development of novel processes.” By providing both a scientific and business perspective on the industry, this report highlights what these logistic barriers are and how they may be overcome by the cutting-edge research happening today.

The report first highlights advances in cell therapies and gene editing and their potential in slowing down the aging process and curing disease. The second part addresses the challenges faced in curing diseases and advancing health, exploring areas such as the microbiome, nano-scale therapies, and personalized medicine. The report includes an exclusive interview with Dr. Trevor Martin, CEO of Mammoth Biosciences, a biotechnology company specializing in developing CRISPR-based diagnostic tools. According to Dr. Martin, he sees “CRISPR systems becoming the platform for a wide variety of applications beyond gene editing over the next 5-10 years.”

“Biotechnology may lead to the creation of new tissue for transplantation, cell, and gene therapies which may lead to cures for chronic diseases and even a treatment for aging,” notes Dr. Sivakumaran. However, improvements in the underlying science are required to power these discoveries, adds Sivakumaran. PreScouter presents this report to serve as a robust primer, highlighting potentially disruptive advances in the field of biotechnology. The report comes as the first chapter of a series of  “disruptors” reports PreScouter will be releasing successively.

About PreScouter, Inc.: PreScouter provides research support services to help business leaders make better R&D, product development, and corporate development decisions. PreScouter’s custom-selected teams of Advanced Degree Researchers and Industrial Experts connect business leaders with new markets, commercializable technologies, industry-impacting startups, and other actionable data. PreScouter’s growing list of 500+ clients includes GE Healthcare, Coca-Cola, BAE Systems, Clorox, and Volvo. For more info, please visit www.prescouter.com.

NICE publishes final recommendation for Almirall’s ILUMETRI®▼ (Tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis

  • Dermatologists in the UK now have an additional biologic treatment option and suitable patients can be considered for treatment with ILUMETRI® (Tildrakizumab)
  • Tildrakizumab is a high-affinity humanized monoclonal antibody that inhibits the p19 subunit of IL-231, that has demonstrated lasting efficacy and safety through 3 years according to the positive results of a pooled analysis2 of two phase III clinical trials
  • Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is due to be marketed in all EU Member states
  • ILUMETRI® received a provisional approval from NICE on March 8th 2019

Almirall, S.A. (ALM)

announced today that the NICE (National Institute for Health and Care Excellence, in the UK) has published its final guidance approving ILUMETRI® (Tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for treating adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.1 Following a single health technology assessment submission to NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, NICE completed their assessment of Tildrakizumab and has recommended Tildrakizumab as a cost effective treatment option for the  NHS for the patients specified in the Final Appraisal Determination (FAD).

Tildrakizumab is a high affinity, humanised, IgG1 K antibody targeting interleukin IL 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis.3 Tildrakizumab constitutes an important step forward in the treatment of moderate-to-severe chronic plaque psoriasis.3

Tildrakizumab is administered by subcutaneous injection. Its convenient dosing regimen, every 3 months during maintenance, could offer convenience and quality of life for patients, potentially achieving an improved treatment satisfaction.4 The low frequency of injections, only 4 doses per year during maintenance, may also encourage adherence.

Almirall in-licensed Tildrakizumab from Sun Pharma Global FZE (Sun Pharma) in May 2016. The agreement is for commercialization of ILUMETRI® (Tildrakizumab) in Europe. It was approved by the European Commission in September 2018, is already available in Germany and is due to be marketed in all EU Member states.

 

Approval based on reSURFACE 1 and reSURFACE 2 phase III trials positive results

Its approval in Europe is based on reSURFACE 1 and 23 positive results, with the dose of 100mg. Both pivotal phase III clinical trials, which included over 1,800 patients from more than 200 clinical sites worldwide, showed that Tildrakizumab offers clinically meaningful benefits over time, which is promising news for patients and physicians.3

According to both studies’ data, an average of 62% of patients achieved 75% of skin clearance (Psoriasis Area Sensitivity Index or PASI 75) by week 12 and an average of 77% at week 28 after only three doses. Moreover, an average of 54% of patients treated with Tildrakizumab 100mg achieved PASI 90 and an average of 23% reached PASI 100 at week 28; while an average of 58% of patients treated with Tildrakizumab 200mg achieved PASI 90 and an average of 29% reached PASI 200 at week 28.5

The results of a pooled analysis through 3 yearsfrom reSURFACE 1 and reSURFACE 2 phase III trials3 show the consistent maintenance of efficacy and safety over 3 years of Tildrakizumab in patients with moderate-to-severe plaque psoriasis who were responders at week 28. According to the data, PASI 75 responses were maintained with continued treatment with Tildrakizumab in 9 out of 10 patients up to week 148.3,4 More than 50% of patients reported that psoriasis no longer affected their lives after only 3 doses.1,3,4 Tildrakizumab was well-tolerated with very low drug-related serious adverse events and discontinuation rates.1,2

 

About Psoriasis

Psoriasis is a chronic immune disease that appears on the skin. It affects an estimated 7.8 million adults in Europe and approximately 125 million people worldwide.6 It is a non-contagious disorder that accelerates the growth cycle of skin cells and results in thick scaly areas of skin. The most common form of psoriasis, called plaque psoriasis, appears as red, raised areas of skin covered with flaky white scales, which may be itchy and painful and can crack and bleed. Despite different treatment options existing, many people with plaque psoriasis continue to struggle with the ongoing, persistent nature of this chronic disease.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.

 

The company, founded more than 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.

 

For more information, please visit almirall.com

 

References

1. ILUMETRI® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9819  Accessed: February 2019

2. Thaçi D, Iversen L, Pau-Charles I, Rozzo S, Blauvelt A, Reich K. Long-term efficacy and safety of Tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. EADV 2018

3. Reich K, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomized controlled, phase 3 trials. Lancet 2017; 390: 276-88

4. Thaci D, et al. Long-term efficacy and safety of Tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. 27th EADV Congress. 12-16 September 2018. Paris, France

5. Kim A. Papp, et al. Efficacy of Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Studies at Weeks 12 and 28. P1724. Presented at the 26th EADV Congress; Geneva, Switzerland; 13-17 September 2017.

6. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Almirall at: https://www.almirall.com/en/patients/report-a-side-effect#344414